89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases, has announced its participation in the H.C. Wainwright 8th Annual MASH Investor Conference. The company's management will take part in a fireside chat and one-on-one investor meetings on Monday, October 7, 2024, at 11:30 AM ET.
Investors and interested parties can access the webcast of the presentation through the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days after the conference. This event provides an opportunity for 89bio to showcase its progress and engage with potential investors in the biopharmaceutical sector.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was -0.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.
The webcast of the presentation will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.